[ad_1] Evox Therapeutics has secured £ 655,000 in funding from Duchenne UK, to support its exosome-based therapeutic platform for the condition. Duchenne is a highly debilitating, progressive, muscle-wasting disorder caused by the …
Read More »[ad_1] Evox Therapeutics has secured £ 655,000 in funding from Duchenne UK, to support its exosome-based therapeutic platform for the condition. Duchenne is a highly debilitating, progressive, muscle-wasting disorder caused by the …
Read More »